http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114606198-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_195370b0a213a8439115ad30a37945cd |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0696 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-074 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
| filingDate | 2022-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f05db68cec1723c5079684b0d8242772 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d7524e4efe513016791065a7149c68e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e3ddf98dcc57a0a88696d83a22e6279 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a17c59a991385959cdd7adb07c16e78e |
| publicationDate | 2022-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-114606198-A |
| titleOfInvention | Osteogenesis imperfect induced pluripotent stem cells and construction method thereof |
| abstract | The invention discloses an osteogenic hypoplasia induced pluripotent stem cell and a construction method thereof. The construction method includes the following steps: S1: introducing a reprogramming factor into somatic cells, and the somatic cells carry a pathogenic mutation site of osteogenic dysplasia; S2: reprogramming the cells obtained in S1 to obtain induced pluripotent stem cells. According to the construction method of the embodiment of the present application, at least the following beneficial effects are obtained: this scheme is aimed at the problem of lack of corresponding iPS cells to understand the pathogenesis of osteogenic dysplasia at present, and targeted use carries the pathogenic mutation site of osteogenic dysplasia In this way, iPS cells with a special disease (osteogenesis imperfecta) were constructed by reprogramming, which laid the foundation for the follow-up study of the disease mechanism of agenesis and the role of specific gene mutations in osteogenesis imperfecta. |
| priorityDate | 2022-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 107.